276 related articles for article (PubMed ID: 11137852)
1. Phosphodiesterase 5 inhibitors and nitrergic transmission-from zaprinast to sildenafil.
Gibson A
Eur J Pharmacol; 2001 Jan; 411(1-2):1-10. PubMed ID: 11137852
[TBL] [Abstract][Full Text] [Related]
2. Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle.
Park K; Moreland RB; Goldstein I; Atala A; Traish A
Biochem Biophys Res Commun; 1998 Aug; 249(3):612-7. PubMed ID: 9731184
[TBL] [Abstract][Full Text] [Related]
3. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension.
Weimann J; Ullrich R; Hromi J; Fujino Y; Clark MW; Bloch KD; Zapol WM
Anesthesiology; 2000 Jun; 92(6):1702-12. PubMed ID: 10839922
[TBL] [Abstract][Full Text] [Related]
4. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
Dunkern TR; Hatzelmann A
Cell Signal; 2005 Mar; 17(3):331-9. PubMed ID: 15567064
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular data on sildenafil citrate: introduction.
Zusman RM
Am J Cardiol; 1999 Mar; 83(5A):1C-2C. PubMed ID: 10078536
[No Abstract] [Full Text] [Related]
6. Peripheral and central activation of nitric oxide-cyclic GMP pathway by sildenafil.
Patil CS; Singh VP; Kulkarni SK
Inflammopharmacology; 2005; 13(5-6):467-78. PubMed ID: 16280099
[TBL] [Abstract][Full Text] [Related]
7. Rabbit corpus cavernosum smooth muscle shows a different phosphodiesterase profile than human corpus cavernosum.
Qiu Y; Kraft P; Lombardi E; Clancy J
J Urol; 2000 Sep; 164(3 Pt 1):882-6. PubMed ID: 10953172
[TBL] [Abstract][Full Text] [Related]
8. Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery.
Pauvert O; Lugnier C; Keravis T; Marthan R; Rousseau E; Savineau JP
Br J Pharmacol; 2003 Jun; 139(3):513-22. PubMed ID: 12788811
[TBL] [Abstract][Full Text] [Related]
9. Sildenafil-induced peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway.
Jain NK; Patil CS; Singh A; Kulkarni SK
Brain Res; 2001 Aug; 909(1-2):170-8. PubMed ID: 11478933
[TBL] [Abstract][Full Text] [Related]
10. New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.
Mason RG
J R Soc Promot Health; 2003 Jun; 123(2):79-80. PubMed ID: 12852189
[No Abstract] [Full Text] [Related]
11. Cyclic GMP phosphodiesterase-5: target of sildenafil.
Corbin JD; Francis SH
J Biol Chem; 1999 May; 274(20):13729-32. PubMed ID: 10318772
[No Abstract] [Full Text] [Related]
12. KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5.
Hirose R; Okumura H; Yoshimatsu A; Irie J; Onoda Y; Nomoto Y; Takai H; Ohno T; Ichimura M
Eur J Pharmacol; 2001 Nov; 431(1):17-24. PubMed ID: 11716838
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.
Turko IV; Ballard SA; Francis SH; Corbin JD
Mol Pharmacol; 1999 Jul; 56(1):124-30. PubMed ID: 10385692
[TBL] [Abstract][Full Text] [Related]
14. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
Chen HH; Huntley BK; Schirger JA; Cataliotti A; Burnett JC
J Am Soc Nephrol; 2006 Oct; 17(10):2742-7. PubMed ID: 16928803
[TBL] [Abstract][Full Text] [Related]
15. Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta.
Mochida H; Inoue H; Takagi M; Noto T; Yano K; Kikkawa K
Eur J Pharmacol; 2002 Apr; 440(1):45-52. PubMed ID: 11959087
[TBL] [Abstract][Full Text] [Related]
16. Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized.
Manganiello V
Mol Pharmacol; 2003 Jun; 63(6):1209-11. PubMed ID: 12761329
[No Abstract] [Full Text] [Related]
17. Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension.
Lewis GD; Semigran MJ
Curr Heart Fail Rep; 2004 Dec; 1(4):183-9. PubMed ID: 16036043
[TBL] [Abstract][Full Text] [Related]
18. NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide.
Kalsi JS; Kell PD; Cellek S; Ralph DJ
Int J Impot Res; 2004 Apr; 16(2):195-200. PubMed ID: 14961060
[TBL] [Abstract][Full Text] [Related]
19. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal.
Atz AM; Wessel DL
Anesthesiology; 1999 Jul; 91(1):307-10. PubMed ID: 10422958
[No Abstract] [Full Text] [Related]
20. The discovery of novel, potent and selective PDE5 inhibitors.
Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
Bioorg Med Chem Lett; 2001 Sep; 11(18):2461-4. PubMed ID: 11549447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
